BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 28802053)

  • 21. Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.
    Tung N; Lin NU; Kidd J; Allen BA; Singh N; Wenstrup RJ; Hartman AR; Winer EP; Garber JE
    J Clin Oncol; 2016 May; 34(13):1460-8. PubMed ID: 26976419
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2.
    Minion LE; Dolinsky JS; Chase DM; Dunlop CL; Chao EC; Monk BJ
    Gynecol Oncol; 2015 Apr; 137(1):86-92. PubMed ID: 25622547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
    Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP
    Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contribution of BRCA1 large genomic rearrangements to early-onset and familial breast/ovarian cancer in Pakistan.
    Rashid MU; Muhammad N; Amin A; Loya A; Hamann U
    Breast Cancer Res Treat; 2017 Jan; 161(2):191-201. PubMed ID: 27826754
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deleterious RAD51C germline mutations rarely predispose to breast and ovarian cancer in Pakistan.
    Rashid MU; Muhammad N; Faisal S; Amin A; Hamann U
    Breast Cancer Res Treat; 2014 Jun; 145(3):775-84. PubMed ID: 24800917
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
    Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z
    Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A recurrent pathogenic BRCA2 exon 5-11 duplication in the Christian Arab population in Israel.
    Reznick Levi G; Larom G; Ofen Glassner V; Ekhilevitch N; Sharon Swartzman N; Paperna T; Baris-Feldman H; Weiss K
    Fam Cancer; 2022 Jul; 21(3):289-294. PubMed ID: 33999380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Germline Mutation in 1338 BRCA-Negative Chinese Hereditary Breast and/or Ovarian Cancer Patients: Clinical Testing with a Multigene Test Panel.
    Kwong A; Shin VY; Chen J; Cheuk IWY; Ho CYS; Au CH; Chan KKL; Ngan HYS; Chan TL; Ford JM; Ma ESK
    J Mol Diagn; 2020 Apr; 22(4):544-554. PubMed ID: 32068069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing.
    Lu HM; Li S; Black MH; Lee S; Hoiness R; Wu S; Mu W; Huether R; Chen J; Sridhar S; Tian Y; McFarland R; Dolinsky J; Tippin Davis B; Mexal S; Dunlop C; Elliott A
    JAMA Oncol; 2019 Jan; 5(1):51-57. PubMed ID: 30128536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of RAD51C as cancer susceptibility gene in a large breast-ovarian cancer patient population referred for genetic testing.
    De Leeneer K; Van Bockstal M; De Brouwer S; Swietek N; Schietecatte P; Sabbaghian N; Van den Ende J; Willocx S; Storm K; Blaumeiser B; Van Asperen CJ; Wijnen JT; Leunen K; Legius E; Michils G; Matthijs G; Blok MJ; Gomez-Garcia E; De Paepe A; Tischkowitz M; Poppe B; Claes K
    Breast Cancer Res Treat; 2012 May; 133(1):393-8. PubMed ID: 22370629
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer.
    Zheng Y; Zhang J; Hope K; Niu Q; Huo D; Olopade OI
    Breast Cancer Res Treat; 2010 Dec; 124(3):857-61. PubMed ID: 20697805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identifying sequence variants contributing to hereditary breast and ovarian cancer in BRCA1 and BRCA2 negative breast and ovarian cancer patients.
    Jarhelle E; Riise Stensland HMF; Hansen GÅM; Skarsfjord S; Jonsrud C; Ingebrigtsen M; Strømsvik N; Van Ghelue M
    Sci Rep; 2019 Dec; 9(1):19986. PubMed ID: 31882575
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients.
    Thompson ER; Boyle SE; Johnson J; Ryland GL; Sawyer S; Choong DY; kConFab ; Chenevix-Trench G; Trainer AH; Lindeman GJ; Mitchell G; James PA; Campbell IG
    Hum Mutat; 2012 Jan; 33(1):95-9. PubMed ID: 21990120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of Germline Mutation in Hereditary Breast and/or Ovarian Cancers by Next-Generation Sequencing on a Four-Gene Panel.
    Kwong A; Shin VY; Au CH; Law FB; Ho DN; Ip BK; Wong AT; Lau SS; To RM; Choy G; Ford JM; Ma ES; Chan TL
    J Mol Diagn; 2016 Jul; 18(4):580-94. PubMed ID: 27157322
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Germline RAD51C mutations in ovarian cancer susceptibility.
    Coulet F; Fajac A; Colas C; Eyries M; Dion-Minière A; Rouzier R; Uzan S; Lefranc JP; Carbonnel M; Cornelis F; Cortez A; Soubrier F
    Clin Genet; 2013 Apr; 83(4):332-6. PubMed ID: 22725699
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer.
    Lin PH; Kuo WH; Huang AC; Lu YS; Lin CH; Kuo SH; Wang MY; Liu CY; Cheng FT; Yeh MH; Li HY; Yang YH; Hsu YH; Fan SC; Li LY; Yu SL; Chang KJ; Chen PL; Ni YH; Huang CS
    Oncotarget; 2016 Feb; 7(7):8310-20. PubMed ID: 26824983
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.
    Tung N; Battelli C; Allen B; Kaldate R; Bhatnagar S; Bowles K; Timms K; Garber JE; Herold C; Ellisen L; Krejdovsky J; DeLeonardis K; Sedgwick K; Soltis K; Roa B; Wenstrup RJ; Hartman AR
    Cancer; 2015 Jan; 121(1):25-33. PubMed ID: 25186627
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutation screening of RAD51C in high-risk breast and ovarian cancer families.
    Lu W; Wang X; Lin H; Lindor NM; Couch FJ
    Fam Cancer; 2012 Sep; 11(3):381-5. PubMed ID: 22476429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutational analysis of RAD51C and RAD51D genes in hereditary breast and ovarian cancer families from Murcia (southeastern Spain).
    Sánchez-Bermúdez AI; Sarabia-Meseguer MD; García-Aliaga Á; Marín-Vera M; Macías-Cerrolaza JA; Henaréjos PS; Guardiola-Castillo V; Peña FA; Alonso-Romero JL; Noguera-Velasco JA; Ruiz-Espejo F
    Eur J Med Genet; 2018 Jun; 61(6):355-361. PubMed ID: 29409816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer.
    Foretová L; Navrátilová M; Svoboda M; Vašíčková P; Sťahlová EH; Házová J; Kleiblová P; Kleibl Z; Macháčková E; Palácová M; Petráková K
    Klin Onkol; 2019; 32(Supplementum2):6-13. PubMed ID: 31409076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.